BioCentury | May 23, 2018
Distillery Therapeutics

Neurology

...plexus neurons. Next steps include testing undisclosed ESR2 agonists in models of gut motor abnormalities. Ausio Pharmaceuticals LLC...
BioCentury | Oct 31, 2011
Company News

Ausio, Marshall Edwards deal

...Marshall Edwards granted Ausio exclusive, worldwide rights to develop and commercialize isoflavone metabolite equol for non-cancer...
...royalties and a royalty-free license to undisclosed manufacturing-related IP from Ausio. Terms were not disclosed. Ausio Pharmaceuticals LLC...
BioCentury | Feb 14, 2011
Clinical News

S-equol: Phase I data

...40 subjects received twice-daily 10-160 mg AUS-131 for 14 days. Data were published in Menopause. Ausio Pharmaceuticals LLC...
Items per page:
1 - 3 of 3
BioCentury | May 23, 2018
Distillery Therapeutics

Neurology

...plexus neurons. Next steps include testing undisclosed ESR2 agonists in models of gut motor abnormalities. Ausio Pharmaceuticals LLC...
BioCentury | Oct 31, 2011
Company News

Ausio, Marshall Edwards deal

...Marshall Edwards granted Ausio exclusive, worldwide rights to develop and commercialize isoflavone metabolite equol for non-cancer...
...royalties and a royalty-free license to undisclosed manufacturing-related IP from Ausio. Terms were not disclosed. Ausio Pharmaceuticals LLC...
BioCentury | Feb 14, 2011
Clinical News

S-equol: Phase I data

...40 subjects received twice-daily 10-160 mg AUS-131 for 14 days. Data were published in Menopause. Ausio Pharmaceuticals LLC...
Items per page:
1 - 3 of 3